Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington’s Disease Mouse Model

26 Jul 2019

Abstract excerpt

Huntington's disease (HD) is a currently incurable and, ultimately, fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion within exon 1 of the huntingtin (HTT) gene, which results in the production of a mutant protein that forms inclusions and selectively destroys neurons in the striatum and other adjacent structures. The RNA-guided Cas9 endonuclease from CRISPR-Cas9 systems is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Genetic Neurodegenerative Diseases
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31465962
DOI: 10.1016/j.omtn.2019.07.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington’s Disease Mouse ModelPMID 31465962Read ↗

Treatment of Huntington’s disease with a pan-HTT-targeting CRISPR nucleaseSemantic proximity Read ↗

An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.Semantic proximity Read ↗

Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q miceSemantic proximity Read ↗

RNA-Targeting CRISPR/Cas13d System Eliminates Disease-Related Phenotypes in Pre-clinical Models of Huntington’s DiseaseSemantic proximity Read ↗

The potential of gene editing for Huntington's disease.Semantic proximity Read ↗

CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.Semantic proximity Read ↗

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.Semantic proximity Read ↗

In vivo CRISPR base editing for treatment of Huntington’s diseaseSemantic proximity Read ↗

In vivo genome editing improves motor function and extends survival in a mouse model of ALS.Semantic proximity Read ↗

Robust nuclease-dead S. aureus dCas9-mediated alpha-synuclein knockdown in substantia nigra in a humanized mouse model of Parkinson’s diseaseSemantic proximity Read ↗

Nuclease-dead S. <i>aureus</i> Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson’s diseaseSemantic proximity Read ↗

CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.